Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy.
about
The noradrenergic action in antidepressant treatments: pharmacological and clinical aspectsPotential contribution of oxidative stress and inflammation to anxiety and hypertensionEffect of acute swim stress on plasma corticosterone and brain monoamine levels in bidirectionally selected DxH recombinant inbred mouse strains differing in fear recall and extinction.Anxiogenic-like effects of chronic cannabidiol administration in rats.Noradrenergic reuptake inhibition in the treatment of pain.Can long-term outcomes be improved by shortening the duration of untreated illness in psychiatric disorders? A conceptual framework.Cannabinoid modulation of alpha2 adrenergic receptor function in rodent medial prefrontal cortexAn enriched rearing environment calms adult male rat sexual activity: implication for distinct serotonergic and hormonal responses to females.Ceruloplasmin deficiency results in an anxiety phenotype involving deficits in hippocampal iron, serotonin, and BDNF.Pharmacotherapy of anxiety disorders: a critical reviewmGluR₁,5 activation improves network asynchrony and GABAergic synapse attenuation in the amygdala: implication for anxiety-like behavior in DBA/2 mice.Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groupsCurrent diagnosis and treatment of anxiety disorders.The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders.Gene therapy in rodent amygdala against fear disorders.New approaches to the pharmacological management of generalized anxiety disorder.Role of atypical antipsychotics in the treatment of generalized anxiety disorder.Psychiatric Conditions in Parkinson Disease: A Comparison With Classical Psychiatric Disorders.Reward memory relieves anxiety-related behavior through synaptic strengthening and protein kinase C in dentate gyrus.The brain, sirtuins, and ageing.The riddle of the sphinx: Sleep, pain, and depression.Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study.Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study.Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration.Protein kinase C is essential for kainate-induced anxiety-related behavior and glutamatergic synapse upregulation in prelimbic cortex.Are antidepressants equally effective in the long-term treatment of major depressive disorder?Pharmacokinetics, distribution, metabolism, and excretion of the dual reuptake inhibitor [(14)C]-nefopam in rats.Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers.The norepinephrine transporter gene is a candidate gene for panic disorder
P2860
Q28300843-1C7500FE-6BFC-4AA6-B6B5-799B15953A8DQ28576099-E3C88127-158C-41DA-ADFD-6795FA0E7497Q30397626-FC63D4A7-2F69-4F62-8637-F6DE29D978A3Q34232627-0327C754-C09E-465F-8778-2E886EEDB23DQ34304397-0ABDFBA7-9978-41F3-BF9C-94B61BB293FBQ34378802-A71D58E6-D69A-4226-8B4A-E1AB911EA507Q34381331-4865CD40-18A6-4930-A2C3-F7AACF184FE7Q35088288-5A79BBE8-4649-4023-9ABC-3D133430E7FBQ35618999-1BB7F624-B86E-41CE-93EE-8ECFAE327F6EQ35686859-44918A0A-A856-4A26-888E-0EF4233FDC9CQ36329100-B9717998-65E3-4893-97BD-3F2665B6616EQ36395440-D6130732-5D41-48A3-84B6-037C91E7F36FQ36771550-B51FD95C-31B9-4658-90CA-2D5667B8B085Q37694597-3F8C7971-ABB5-4984-9A8B-241F686579CFQ37775958-651A74B8-9C4D-4AEE-A2D5-53C85B7955C1Q38071131-35F3A921-E4EA-4BFA-88CA-41CA24BDA2F5Q38209188-E8FA1F05-A414-490E-8E3B-225520F2E2C7Q38588201-9DC95793-52C5-4EE1-A2FC-A4A235A65E7EQ39182365-40C426B4-D224-44CF-A24D-542AF623D8E7Q39313687-A7C54360-9D95-4C78-8993-C16895AE6968Q42423653-6A5C0590-1E57-4271-A99E-73DC19761E93Q43450686-1EC1BDF1-8793-4BE8-A182-A4D19C1EDD3BQ45413391-361AE982-9C71-46FF-93F2-E7E1FF936CC2Q47695816-B36B7911-733D-4712-8F62-AC25CBCD6FF9Q47820916-CB62AD0F-07CF-404A-9DE3-C37E5D284E43Q48176372-C79506A3-8A13-4445-8032-40697A0D24CAQ50251124-25F98B24-9FAF-4800-A3A0-2BFFC7330504Q55059545-D4916060-AC0C-425E-9C92-EABBB8FFC23FQ58864945-1CB214E6-3EB1-4E14-8860-9C50416D3533
P2860
Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serotonin norepinephrine reupt ...... ew of their clinical efficacy.
@en
Serotonin norepinephrine reuptake inhibitors
@nl
type
label
Serotonin norepinephrine reupt ...... ew of their clinical efficacy.
@en
Serotonin norepinephrine reuptake inhibitors
@nl
prefLabel
Serotonin norepinephrine reupt ...... ew of their clinical efficacy.
@en
Serotonin norepinephrine reuptake inhibitors
@nl
P2860
P356
P1476
Serotonin norepinephrine reupt ...... ew of their clinical efficacy.
@en
P2093
A Carlo Altamura
David S Baldwin
P2860
P356
10.1002/HUP.1074
P577
2010-01-01T00:00:00Z